Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

IGC Pharma Inc

IGC ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.24

▼ -1.02%

Market Cap $25.07M · Vol 13.83K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$25.07M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

30.82

Momentum

Beta

0.51

vs Market

52W High

$0.45

45.56% below

52W Low

$0.24

3.81% above

Volume

13.83K

Avg 52.48K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

86.83%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, IGC Pharma Inc (IGC) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IGC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.73%

-11.50%

-9.21%

-23.89%

YTD

-13.82%

-37.84%

-21.32%

-83.50%

Financials & Valuation

TTM · Annual

Total Revenue	$869.00K
Net Income	$-4,146,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	21.58
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	103.38M

Technical Indicators

50-Day SMA	$0.28
200-Day SMA	$0.28
RSI (14)	30.82
Beta	0.51
52-Week High	$0.45
52-Week Low	$0.24

Volume Today	13.83K
Avg Daily Volume (30D)	52.48K
Relative Volume	0.26x
Volatility (10D)	33.98
Volatility (30D)	39.05
Free Float	86.83%

Analyst Consensus

BUY

Current Price $0.24

Mean Target $4.00

52W Low$0.24 52W High$0.45

Current

Target

$0.24 $0.45

Current Analyst target

+1,549.48% upside potential · 0 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG001SQQKX0

ISINUS45408X3089

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LONN.S Lonza Group AG -0.22% ONC BeOne Medicines AG +0.51% 068270.KS Celltrion, Inc. +0.10% MEDP Medpace Holdings, Inc. +6.43% CRL Charles River Laboratories International, Inc. +9.33%

Company Profile

IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.